+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis



Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis



Gastroenterology Research 7(2): 51-55



Pouchitis is a relatively common complication that develops following ileal pouch-anal anastomosis in patients with complicated ulcerative colitis (UC). Both pouchitis and UC share similarities in their development, as well as in the mechanisms involving mediators of the inflammatory process. In the recent years, the discovery and investigation of biological therapies have led to advancement in the management of these disorders, and the continuation of research on this novel area holds strong implications for a future reduction in the use of invasive surgical procedures. Alicaforsen represents one of these emerging therapeutic agents, and has demonstrated promising results in both preclinical and clinical settings. This article reviews the therapeutic effects of alicaforsen for the management of UC and refractory pouchitis, with special emphasis on the mechanism of action of this therapeutic agent and the clinical studies asserting its effectiveness.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057158684

Download citation: RISBibTeXText

PMID: 27785270


Related references

Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. Arzneimittel-Forschung 48(11): 1091-1096, 1998

Cyclosporin A retention enemas in refractory distal ulcerative colitis and pouchitis. Scandinavian Journal Of Gastroenterology. 28(8): 701-704, 1993

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Alimentary Pharmacology & Therapeutics 23(10): 1427-1434, 2006

Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Alimentary Pharmacology & Therapeutics 17(10): 1263-1271, 2003

M2053 False Positive Celiac Serology Is Associated with Refractory Pouchitis in Patients with Ulcerative Colitis. Gastroenterology 136(5): A-475, 2009

Are ASCA ulcerative colitis patients at higher risk for refractory pouchitis and pouch fistulae?. Gastroenterology 118(4 Suppl 2 Part 1): A106, 2000

Successful treatment with tacrolimus of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for ulcerative colitis. Immunological Medicine 41(3): 142-146, 2018

Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology Journal 4(1): 97, 2016

An uncommon complication of chronic antibiotics refractory pouchitis after ileal pouch-anal anastomosis for ulcerative colitis. Gastroenterology 147(4): 743-744, 2014

Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. Journal of the Royal College of Surgeons of Edinburgh 46(6): 334-337, 2001

Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. Digestive Surgery 21(3): 197-201, 2004

Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. Digestive Diseases 36(2): 123-129, 2018

Clinical Features of Refractory Pouchitis with Penetrating Lesions and the Efficacy of Infliximab Treatment for Patients with Ulcerative Colitis after Restorative Proctocolectomy. Digestion 92(3): 147-155, 2015

Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study. Therapeutic Advances in Gastroenterology 10(2): 199-206, 2017

Early first episode of pouchitis after ileal pouch-anal anastomosis for pediatric ulcerative colitis is a risk factor for development of chronic pouchitis. Journal of Pediatric Surgery 54(9): 1788-1793, 2019